肿瘤免疫治疗相关预测生物标志物研究进展

国际肿瘤学杂志››2020,Vol. 47››Issue (8): 487-491.doi:10.3760/cma.j.cn371439-20191105-00062

肿瘤免疫治疗相关预测生物标志物研究进展

张敏, 周丽娜, 徐姗姗, 陈骏()

大连医科大学附属第二医院肿瘤科 116000

收稿日期:2019-11-05修回日期:2020-03-11出版日期:2020-08-08发布日期:2020-10-22
通讯作者:陈骏 E-mail:chenjundl@vip.sina.com
基金资助:
希思科-君实肿瘤免疫研究基金(Y-JS2019-034)

Research progress in predictive biomarkers related to tumor immunotherapy

Zhang Min, Zhou Lina, Xu Shanshan, Chen Jun()

Department of Oncology, Second Hospital of Dalian Medical University, Dalian 116000, China

Received:2019-11-05Revised:2020-03-11Online:2020-08-08Published:2020-10-22
Contact:Chen Jun E-mail:chenjundl@vip.sina.com
Supported by:
CSCO-Junshi Tumor Immunotherapy Clinical Research Fund(Y-JS2019-034)

摘要/Abstract

摘要：

肿瘤免疫治疗是一种主要针对程序性死亡蛋白-1(PD-1)及其配体PD-L1的治疗方法。PD-1/PD-L1抑制剂在多种肿瘤中具有非常明显的临床获益和持久反应,但是整体反应率仍较低。研究发现PD-L1和肿瘤突变负荷可以预测免疫治疗效果,MSI-H/dMMR、TP53和KRAS等基因突变与免疫治疗疗效呈正相关;而MDM2/4、EGFR、ALK等基因则与免疫治疗效果呈负相关。

张敏, 周丽娜, 徐姗姗, 陈骏. 肿瘤免疫治疗相关预测生物标志物研究进展[J]. 国际肿瘤学杂志, 2020, 47(8): 487-491.

Zhang Min, Zhou Lina, Xu Shanshan, Chen Jun. Research progress in predictive biomarkers related to tumor immunotherapy[J]. Journal of International Oncology, 2020, 47(8): 487-491.

参考文献29

[1]	Champiat S, Ferrara R, Massard C, et al. Hyperprogressive disease: recognizing a novel pattern to improve patient management[J]. Nat Rev Clin Oncol, 2018,15(12):748-762. DOI: 10.1038/s41571-018-0111-2. doi:10.1038/s41571-018-0111-2pmid:30361681
[2]	Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial[J]. Lancet, 2016,387(10027):1540-1550. DOI: 10.1016/S0140-6736(15)01281-7. doi:10.1016/S0140-6736(15)01281-7pmid:26712084
[3]	Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer[J]. N Engl J Med, 2016,375(19):1823-1833. DOI: 10.1056/NEJMoa1606774.
[4]	Reck M, Rodríguez-Abreu D, Robinson AG, et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemothe-rapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater[J]. J Clin Oncol, 2019,37(7):537-546. DOI: 10.1200/JCO.18.00149. doi:10.1200/JCO.18.00149pmid:30620668
[5]	Burgess EF, Livasy C, Hartman A, et al. Discordance of high PD-L1 expression in primary and metastatic urothelial carcinoma lesions[J]. Urol Oncol, 2019,37(5):299.e19-299.e25. DOI: 10.1016/j.urolonc.2019.01.002.
[6]	Li M, Li A, Zhou S, et al. Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer[J]. BMC Cancer, 2018,18(1):4. DOI: 10.1186/s12885-017-3916-y. pmid:29291717
[7]	Hong LZ, Dibaj S, Negrao MV, et al. Spatial and temporal heterogeneity of PD-L1 and its impact on benefit from immune checkpoint blockade in non-small cell lung cancer (NSCLC)[J]. J Clin Oncol, 2019, 37 Supple 15 9017. DOI: 10.1200/JCO.2019.37.15_suppl.9017.
[8]	Meng X, Huang Z, Teng F, et al. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy[J]. Cancer Treat Rev, 2015,41(10):868-876. DOI: 10.1016/j.ctrv.2015.11.001.
[9]	Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden[J]. N Engl J Med, 2018,378(22):2093-2104. DOI: 10.1056/NEJMoa1801946.
[10]	Goodman AM, Kato S, Bazhenova L, et al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers[J]. Mol Cancer Ther, 2017,16(11):2598-2608. DOI: 10.1158/1535-7163.MCT-17-0386. pmid:28835386
[11]	Wang Z, Duan J, Cai S, et al. Assessment of blood tumor mutational burden as a potential biomarker for immunotherapy in patients with non-small cell lung cancer with use of a next-generation sequencing cancer gene panel[J]. JAMA Oncol, 2019,5(5):696-702. DOI: 10.1001/jamaoncol.2018.7098. pmid:30816954
[12]	Samstein RM, Lee CH, Shoushtari AN, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types[J]. Nat Gene, 2019,51(2):202-206. DOI: 10.1038/s41588-018-0312-8.
[13]	O'Neil BH, Wallmark JM, Lorente D, et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma[J]. PLoS One, 2017,12(12):e0189848. DOI: 10.1371/journal.pone.0189848.
[14]	Soussi T, Wiman KG. TP53: an oncogene in disguise[J]. Cell Death Differ, 2015,22(8):1239-1249. DOI: 10.1038/cdd.2015.53.
[15]	Gibbons DL, Byers LA, Kurie JM. Smoking, p53 mutation, and lung cancer[J]. Mol Cancer Res, 2014,12(1):3-13. DOI: 10.1158/1541-7786.MCR-13-0539.
[16]	Biton J, Mansuet-Lupo A, Pécuchet N, et al. TP53, STK11, and EGFR mutations predict tumor immune profile and the response to anti-PD-1 in lung adenocarcinoma[J]. Clin Cancer Res, 2018,24(22):5710-5723. DOI: 10.1158/1078-0432.CCR-18-0163.
[17]	Cortez MA, Ivan C, Valdecanas D, et al. PDL1 regulation by p53 via miR-34[J]. J Natl Cancer Inst, 2016, 108(1): djv303. DOI: 10.1093/jnci/djv303.
[18]	Ji M, Liu Y, Li Q, et al. PD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutations[J]. Cancer Biol Ther, 2016,17(4):407-413. DOI: 10.1080/15384047.2016.1156256.
[19]	Dong ZY, Zhong WZ, Zhang XC, et al. Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma[J]. Clin Cancer Res, 2017,23(12):3012-3024. DOI: 10.1158/1078-0432.CCR-16-2554.
[20]	Champiat S, Dercle L, Ammari S, et al. Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1[J]. Clin Cancer Res, 2017,23(8):1920-1928. DOI: 10.1158/1078-0432.CCR-16-1741. pmid:27827313
[21]	Kato S, Goodman A, Walavalkar V, et al. Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate[J]. Clin Cancer Res, 2017,23(15):4242-4250. DOI: 10.1158/1078-0432.CCR-16-3133. pmid:28351930
[22]	Gainor JF, Shaw AT, Sequist LV, et al. EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis[J]. Clin Cancer Res, 2016,22(18):4585-4593. DOI: 10.1158/1078-0432.CCR-15-3101. pmid:27225694
[23]	Bassi C, Ho J, Srikumar T, et al. Nuclear PTEN controls DNA repair and sensitivity to genotoxic stress[J]. Science, 2013,341(6144):395-399. DOI: 10.1126/science.1236188. doi:10.1126/science.1236188pmid:23888040
[24]	Peng W, Chen JQ, Liu C, et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy[J]. Cancer Discov, 2016,6(2):202-216. DOI: 10.1158/2159-8290.CD-15-0283. pmid:26645196
[25]	Zaretsky JM, Garcia-Diaz A, Shin DS, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma[J]. N Engl J Med, 2016,375(9):819-829. DOI: 10.1056/NEJMoa1604958.
[26]	Duruisseaux M, Martínez-Cardús A, Calleja-Cervantes ME, et al. Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis[J]. Lancet Respir Med, 2018,6(10):771-781. DOI: 10.1016/S2213-2600(18)30284-4.
[27]	Domingo E, Freeman-Mills L, Rayner E, et al. Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study[J]. Lancet Gastroenterol Hepatol, 2016,1(3):207-216. DOI: 10.1016/S2468-1253(16)30014-0.
[28]	Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer[J]. Science, 2015,348(6230):124-128. DOI: 10.1126/science.aaa1348. pmid:25765070
[29]	Wakelee H, Aredo J, Vali S, et al. Prediction of PD-1 immunothe-rapy (IO) response for KRAS mutated non-small cell lung cancer (NSCLC) based on co-mutations using a computational biological model[J]. Ann Oncol, 2018, 29 Suppl 8: viii510-viii511. DOI: 10.1093/annonc/mdy292.